Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6214622

Title:Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
Inventors:Treco, Douglas; Arlington, MA, USA
Summary:This invention describes a method of gene or DNA targeting in cells of vertebrate, particularly mammalian, origin, via the introduction of DNA into primary or secondary cells of vertebrate origin through homologous recombination or targeting of the DNA, which is introduced into genomic DNA of the primary or secondary cells at a preselected site. Further described are primary or secondary cells, referred to as homologously recombinant (HR) primary or secondary cells, as well as uses of the homologously recombinant primary or secondary cells. Also disclosed is a method of turning on a gene present in primary cells, secondary cells or immortalized cells of vertebrate origin, which is normally not expressed in the cells or is not expressed at significant levels in the cells.
Abstract:The present invention relates to a method of gene or DNA targeting in cells of vertebrate, particularly mammalian, origin. That is, it relates to a method of introducing DNA into primary or secondary cells of vertebrate origin through homologous recombination or targeting of the DNA, which is introduced into genomic DNA of the primary or secondary cells at a preselected site. The present invention further relates to primary or secondary cells, referred to as homologously recombinant (HR) primary or secondary cells, produced by the present method and to uses of the homologously recombinant primary or secondary cells. The present invention also relates to a method of turning on a gene present in primary cells, secondary cells or immortalized cells of vertebrate origin, which is normally not expressed in the cells or is not expressed at significant levels in the cells.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6214622
Application Number:US1995000446928
Date Filed:18/05/1995
Date Published:10/04/2001
Assignee:Transkaryotic Therapies, Inc., Cambridge, MA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/5/2020